Screener
Summit Therapeutics SMMT Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| General and administrative | 62,594 | 15,586 |
| Total operating expenses | 195,212 | 66,851 |
| Other income, net | 5,788 | 3,938 |
| Net loss | $(189,424) | $(62,913) |
| Net loss per share: | ||
| Basic and diluted | $(0.24) | $(0.09) |
| Weighted average common shares outstanding: | ||
| Basic and diluted | 775,458,141 | 738,076,003 |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's business segments — net loss?
- Summit Therapeutics (SMMT) reported business segments — net loss of -$189.42M in Q1 2026.
- How has Summit Therapeutics's business segments — net loss changed year-over-year?
- Summit Therapeutics's business segments — net loss decreased by 201.1% year-over-year, from -$62.91M to -$189.42M.
- What is the long-term trend for Summit Therapeutics's business segments — net loss?
- Over 3 years (2022 to 2025), Summit Therapeutics's business segments — net loss has grown at a 139.3% compound annual growth rate (CAGR), from -$78.78M to -$1.08B.
- What does business segments — net loss mean?
- The final bottom-line result for the segment after subtracting all operating and non-operating expenses from total revenues. For development-stage biotechs, this represents the capital consumed to advance the product pipeline.
Ask your AI about Summit Therapeutics's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude